AbbVie  
1Q Revenues: $7.8 billion (flat)
1Q Earnings: $2.5 billion (-12%)
Comments: Global HUMIRA revenues were $4.4 billion in the quarter, down 6%. Global revenues from the hematologic oncology portfolio were up 43% to $1.2 billion. Global IMBRUVICA revenues were $1.0 billion, with U.S. net revenues of $829 million and international profit sharing of $193 million. Global VENCLEXTA revenues were $151 million. Global HCV revenues were $815 million, down 11%. In the U.S., HCV net revenues of $403 million grew 17% in the quarter.